New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 8, 2013
10:52 EDTCLDXCelldex stages turnaround, levels to watch
The stock is a mirror image of yesterday's sharp downside action following earnings, that later saw the shares level out to close near the opening gap price near $10.50. Today the stock is up over 13.5%, last at $11.91. Several firms, Cantor, Roth Capital, and Jefferies all raised price targets on the shares this morning, ranging from $15 to $16. At current levels, next resistance is at $12.53, a prior pivot high. Support is at $11.36.
News For CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
08:07 EDTCLDXCelldex appoints Richard Wright as Chief Commercial Officer
Celldex Therapeutics announced the promotion of Richard Wright, Ph.D. to SVP and the newly created position of Chief Commercial Officer. Dr. Wright was previously Vice President of Commercial Operations at Celldex and brings nearly 25 years of industry experience, including the commercialization of six successful drug therapies. As Chief Commercial Officer, Dr. Wright is responsible for developing global business strategy and building the infrastructure required to support commercialization of Celldex's cancer immunotherapy pipeline.
June 29, 2015
08:26 EDTCLDXCelldex announces independent DSMB recommends continuation of Rintega study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use